Swine Fever Vaccine Offers Protection and Also Triggers Immune Response in Vaccinated Pigs
 |
| Swine Fever Vaccine |
African swine fever (ASF) is a devastating disease that affects wild boar and domestic pigs. It is one of the most serious animal diseases worldwide. The virus is endemic in Africa, it has also spread to Asia, Europe, and Russia. However, its arrival could disrupt commercial pork production and pig farming. ASF can cause chronic disease, as well as death.
This infectious disease is highly virulent and can quickly infect a wide range of swine. The virus replicates in resident macrophages and reticular cells. It is characterized by a large double-stranded nucleocytoplasmic DNA molecule with 250-nm diameter. During replication, the virions contain an icosahedron protein capid, which is a type of cellular phagocytic membrane. The virus is also easily transmissible. It is not always possible to diagnose its presence early enough to prevent the disease from spreading. Researchers have developed vaccine candidates for protecting swine against the virus. Although a lot of work has been done to develop these vaccines, it is not yet clear how well they will protect swine against the disease.
The global Swine Fever Vaccine Market is estimated to be valued at US$ 2,724.5 million in 2022 and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).
Most experimental ASF vaccines have been tested on animals in a laboratory setting. While they have demonstrated some safety, these tests are not sufficient for approval of their use in the field. When developing a vaccine, it is crucial to test it on a range of genotypes, including a wide range of virulent strains. This is not an easy task, as many of the viral strains have been isolated from different countries and regions. There are 24 known ASFV genotypes, and the virulence of these strains can vary widely.
Currently, most experimental ASF vaccines are targeted at strains that are circulating in Europe and Africa. They are also less likely to cross-protect against strains with more distant phylogenetical relationships than the ones they are designed to target. Therefore, they are at greater risk of causing recombination events between strains that are unlicensed. Recombination can be extremely harmful, as it can lead to the evolution of an ASFV strain that is more virulent than the one used in the vaccine.
One major concern is that the vaccinated pigs develop symptoms and show signs of disease shortly after the vaccination. While some studies have indicated that this happens in a small percentage of vaccinated pigs, a substantial number of pigs have developed unacceptable reactions following vaccination. Boehringer Ingelheim gained a New Veterinary Drug Registration Certificate for Ingelvac CSF MLV from the Ministry of Agriculture and Rural Affairs of China in June 2020. This is the first CSF live vaccine joinlt developed by multinational companies and Chinese research institutes.
This infectious disease is highly virulent and can quickly infect a wide range of swine. The virus replicates in resident macrophages and reticular cells. It is characterized by a large double-stranded nucleocytoplasmic DNA molecule with 250-nm diameter. During replication, the virions contain an icosahedron protein capid, which is a type of cellular phagocytic membrane. The virus is also easily transmissible. It is not always possible to diagnose its presence early enough to prevent the disease from spreading. Researchers have developed vaccine candidates for protecting swine against the virus. Although a lot of work has been done to develop these vaccines, it is not yet clear how well they will protect swine against the disease.
The global Swine Fever Vaccine Market is estimated to be valued at US$ 2,724.5 million in 2022 and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).
Most experimental ASF vaccines have been tested on animals in a laboratory setting. While they have demonstrated some safety, these tests are not sufficient for approval of their use in the field. When developing a vaccine, it is crucial to test it on a range of genotypes, including a wide range of virulent strains. This is not an easy task, as many of the viral strains have been isolated from different countries and regions. There are 24 known ASFV genotypes, and the virulence of these strains can vary widely.
Currently, most experimental ASF vaccines are targeted at strains that are circulating in Europe and Africa. They are also less likely to cross-protect against strains with more distant phylogenetical relationships than the ones they are designed to target. Therefore, they are at greater risk of causing recombination events between strains that are unlicensed. Recombination can be extremely harmful, as it can lead to the evolution of an ASFV strain that is more virulent than the one used in the vaccine.
One major concern is that the vaccinated pigs develop symptoms and show signs of disease shortly after the vaccination. While some studies have indicated that this happens in a small percentage of vaccinated pigs, a substantial number of pigs have developed unacceptable reactions following vaccination. Boehringer Ingelheim gained a New Veterinary Drug Registration Certificate for Ingelvac CSF MLV from the Ministry of Agriculture and Rural Affairs of China in June 2020. This is the first CSF live vaccine joinlt developed by multinational companies and Chinese research institutes.
Comments
Post a Comment